Edition:
United States

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

1.49USD
18 Apr 2018
Change (% chg)

$0.06 (+4.20%)
Prev Close
$1.43
Open
$1.45
Day's High
$1.51
Day's Low
$1.43
Volume
10,054
Avg. Vol
89,093
52-wk High
$3.75
52-wk Low
$0.78

Chart for

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $23.26
Shares Outstanding(Mil.): 16.21
Dividend: --
Yield (%): --

Financials

  AEZS.OQ Industry Sector
P/E (TTM): -- 199.23 33.71
EPS (TTM): -1.13 -- --
ROI: -76.55 -0.66 13.09
ROE: -979.64 -2.84 14.92

BRIEF-Aeterna Zentaris Qtrly Loss Per Share $0.03

* AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

Mar 28 2018

BRIEF-Aeterna Zentaris Appoints James Clavijo As CFO

* AETERNA ZENTARIS APPOINTS JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER

Mar 05 2018

BRIEF-Aeterna Zentaris Provides Update On Previously Disclosed Class Action Lawsuit

* AETERNA ZENTARIS PROVIDES UPDATE ON PREVIOUSLY DISCLOSED CLASS ACTION LAWSUIT

Mar 05 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

Jan 17 2018

BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore

* AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE

Dec 22 2017

BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris

* DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS

Dec 21 2017

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency.

Dec 20 2017

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Dec 20 Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018.

Dec 20 2017

BRIEF-Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency

* AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY

Dec 20 2017

BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer

* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER

Dec 08 2017

Earnings vs. Estimates